Communication strategy for novel MOA in neurological disorder

Optimizing communication strategies for stakeholder and scientific alignment

Our client had a molecule recognized for its efficacy in reducing innate immunogenicity, previously applied in other therapeutic areas. They sought to extend its application to a degenerative neurological disorder, which posed a significant departure from their established therapeutic areas.

The challenge

The client faced significant challenges in advancing their molecule’s clinical development for a degenerative neurological disorder due to limited data and scientific support for their unconventional therapeutic approach. In this context, they needed to identify the most efficient and cost‑effective strategy to communicate scientific rationale, engage stakeholders, and support program advancement.

The Acumetis approach

1. Created a high-level narrative aligning the MOA with the new indication, leveraging data and aspirational statements to guide evidence generation.
2. A communication strategy was developed, focusing on the evolution of the desired narrative over time pre- and post-data readout.
3. High ROI activities were identified, which required strong academic KOL engagement and focused congress presentations.
4. Advisory boards were organized with experts on disease pathophysiology and the relevance of the MOA. We identified critical biomarkers for investigation and publication to bolster the communication strategy.
5. Key abstracts and posters were prepared for priority regional congresses, offering a cost-effective method to disseminate information to key stakeholders.

The outcome and why it worked

The approach enabled refined scientific communication through structured KOL engagement, targeted congress activity, and iterative feedback. By aligning stakeholder expectations with the evolving evidence base, the strategy strengthened scientific credibility, supported confident decision‑making, and maintained development momentum as the program advanced.

Acumetis medical affairs team

Acumetis medical affairs partners with biopharma teams to know the science and own the narrative, turning scientific strategy, evidence generation, and medical communications into credible stories that shape decisions and build confidence. Our teams anticipate evidence needs early and work across functions to ensure clinical endpoints, evidence plans, and communications are rigorous, relevant, and aligned with regulatory expectations.